279 related articles for article (PubMed ID: 24737887)
21. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
[TBL] [Abstract][Full Text] [Related]
22. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Wang Q; Weisberg E; Zhao JJ
Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925
[TBL] [Abstract][Full Text] [Related]
23. The Phosphatidylinositol 3-Kinase p110α/PTEN Signaling Pathway Is Crucial for HIV-1 Entry.
Hamada K; Maeda Y; Mizutani A; Okada S
Biol Pharm Bull; 2019; 42(1):130-138. PubMed ID: 30606984
[TBL] [Abstract][Full Text] [Related]
24. Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity.
Stengel C; Jenner E; Meja K; Mayekar S; Khwaja A
Br J Haematol; 2013 Jul; 162(2):285-9. PubMed ID: 23594092
[No Abstract] [Full Text] [Related]
25. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.
Cizmecioglu O; Ni J; Xie S; Zhao JJ; Roberts TM
Elife; 2016 Oct; 5():. PubMed ID: 27700986
[TBL] [Abstract][Full Text] [Related]
26. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α.
Baer R; Cintas C; Dufresne M; Cassant-Sourdy S; Schönhuber N; Planque L; Lulka H; Couderc B; Bousquet C; Garmy-Susini B; Vanhaesebroeck B; Pyronnet S; Saur D; Guillermet-Guibert J
Genes Dev; 2014 Dec; 28(23):2621-35. PubMed ID: 25452273
[TBL] [Abstract][Full Text] [Related]
28. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.
Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ
Nature; 2008 Aug; 454(7205):776-9. PubMed ID: 18594509
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
30. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
Kinross KM; Montgomery KG; Kleinschmidt M; Waring P; Ivetac I; Tikoo A; Saad M; Hare L; Roh V; Mantamadiotis T; Sheppard KE; Ryland GL; Campbell IG; Gorringe KL; Christensen JG; Cullinane C; Hicks RJ; Pearson RB; Johnstone RW; McArthur GA; Phillips WA
J Clin Invest; 2012 Feb; 122(2):553-7. PubMed ID: 22214849
[TBL] [Abstract][Full Text] [Related]
31. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
[TBL] [Abstract][Full Text] [Related]
32. PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes.
White AR; Tiwari D; MacLeod MC; Danzer SC; Gross C
Neurobiol Dis; 2020 Oct; 144():105026. PubMed ID: 32712265
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers.
Kaysudu I; Gungul TB; Atici S; Yilmaz S; Bayram E; Guven G; Cizmecioglu NT; Sahin O; Yesiloz G; Haznedaroglu BZ; Cizmecioglu O
Cancer Sci; 2023 Nov; 114(11):4365-4375. PubMed ID: 37706278
[TBL] [Abstract][Full Text] [Related]
34. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM
Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162
[TBL] [Abstract][Full Text] [Related]
35. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
36. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Gao X; Wang Y; Ribeiro CF; Manokaran C; Chang H; Von T; Rodrigues S; Cizmecioglu O; Jia S; Korpal M; Korn JM; Wang Z; Schmit F; Jiang L; Pagliarini R; Yang Y; Sethi I; Signoretti S; Yuan GC; Loda M; Zhao JJ; Roberts TM
Mol Cancer Res; 2022 May; 20(5):673-685. PubMed ID: 35105671
[TBL] [Abstract][Full Text] [Related]
37. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
[TBL] [Abstract][Full Text] [Related]
38. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.
Guillermet-Guibert J; Bjorklof K; Salpekar A; Gonella C; Ramadani F; Bilancio A; Meek S; Smith AJ; Okkenhaug K; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8292-7. PubMed ID: 18544649
[TBL] [Abstract][Full Text] [Related]
39. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
40. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]